| Meridia (sibutramine) / AbbVie |
NCT00044187: The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder |
|
|
| Completed | 4 | 130 | US | Sibutramine | Eli Lilly and Company | Schizophrenia, Psychotic Disorders, Bipolar Disorder | | 09/03 | | |
NCT00234988: A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects. |
|
|
| Completed | 4 | 93 | US | sibutramine hydochloride monohydrate, ABT-991, sibutramine, Meridia | Abbott | Obesity | 01/06 | | | |
NCT00463112: Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS |
|
|
| Completed | 4 | 80 | Europe | Sibutramine | Hippocration General Hospital | Obesity, Polycystic Ovary Syndrome | | 09/06 | | |
NCT00729963: Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients |
|
|
| Completed | 4 | 45 | Canada | Sibutramine, CPAP | Laval University | Obstructive Sleep Apnea, Obesity, Hypertension | 09/07 | 09/07 | | |
NCT00433641: Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes |
|
|
| Completed | 4 | 181 | US | sibutramine, meridia, MERIDIA | Mayo Clinic, National Institutes of Health (NIH) | Obesity | 11/07 | 11/07 | | |
| Terminated | 4 | 390 | US | group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition | Pennington Biomedical Research Center, Louisiana Office of Group Benefits | Obesity | 12/07 | 01/08 | | |
NCT01475019: The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) |
|
|
| Unknown status | 4 | 200 | Europe | Orlistat, Sibutramine, Diet and physical exercise | Aristotle University Of Thessaloniki | Obesity, Polycystic Ovaries Syndrome | 01/10 | 12/12 | | |
NCT01170364: Studying the Effects of Sibutramine on Eating Behavior |
|
|
| Terminated | 4 | 14 | US | Sibutramine, Meridia, Placebo, sugar pill | New York State Psychiatric Institute, AstraZeneca | Obesity | 10/10 | 10/10 | | |
NCT00537810: Treatment of Binge Eating in Obese Patients in Primary Care |
|
|
| Completed | 4 | 104 | US | Sibutramine, Meridia, Placebo, Self-help CBT + Sibutramine, Self-help CBT + Placebo | Yale University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity, Binge Eating | 10/12 | 10/12 | | |
2005-002080-88`ACTRN12616001707459: A double−blind, placebo−controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal |
|
|
| Ongoing | 4 | 36 | Europe | Reductil 10 mg, Reductil 15 mg, PL 00037/0326, PL 00037/0327, Reductil 10 mg, Reductil 15 mg, Reductil 10 mg, Reductil 15 mg | Aintree Hospitals NHS Trust and University of Liverpool, The Prostate Cancer Foundation of Australia: Movember Clinical Trial Award | Prostate Cancer progression, Vitamin D in preventing prostate cancer progression | | | | |
2009-013737-24: TRATAMIENTO MULTIDISCIPLINARIO DE LA OBESIDAD MÓRBIDA: MEDICAMENTOS, TERAPIA DE COMPORTAMIENTO, APOYO NUTRICIONAL Y ACTIVIDAD FÍSICA. ESTDIO TRAMOMTANA |
|
|
| Ongoing | 4 | 60 | Europe | Reductil, 63823, | HOSPITAL UNIVERSITARIO SON DURETA. UNIDAD DE INVESTIGACIÓN | terapia complementaria dentro de un programa integral parael control del peso en:- Pacientes con obesidad, cuyo IMC (Índice de Masa Corporal) es 30 kg/m2 o superior- Pacientes con sobrepeso, cuyo IMC es 27 kg/m2 o superior, que presenten otros factoresde riesgo asociados a la obesidad como diabetes tipo 2 o dislipidemia. | | | | |
NCT05821543: Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity |
|
|
| Completed | 4 | 240 | RoW | metformin+sibutramine, Reduxin® Forte, sibutramine+ microcrystalline cellulose, Reduxin® | Promomed, LLC | Obesity | 05/21 | 05/21 | | |
